Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Enzon's PEG-SN38 Shows Anti-Tumor Activity in Resistant Preclinical Tumor Models
May 1st, 2007
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced new preclinical data showing that treatment with PEG-SN38, Enzon's PEGylated SN38 compound, resulted in significant tumor growth inhibition in mice resistant to Camptosar(R) (irinotecan HCl injection) and outperformed Camptosar in mice when given as a second round therapy. Additionally, PEG-SN38 demonstrated long-lasting antitumor activity in mouse models of human breast and pancreatic cancers. The data were presented at the American Association for Cancer Research (AACR) annual meeting in Los Angeles, April 14-18, 2007. "This exciting new data showing PEG-SN38's activity in resistant tumors combined with the...
Source: Cancer Weekly (2007-05-01)
|
